BioMarin Pharmaceuticals BMRN Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's inventories?
- BioMarin Pharmaceuticals (BMRN) reported inventories of $1.27B in Q1 2026.
- How has BioMarin Pharmaceuticals's inventories changed year-over-year?
- BioMarin Pharmaceuticals's inventories decreased by 0.1% year-over-year, from $1.27B to $1.27B.
- What is the long-term trend for BioMarin Pharmaceuticals's inventories?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's inventories has grown at a 13.2% compound annual growth rate (CAGR), from $698.55M to $1.3B.
- What does inventories mean?
- The total value of all products and materials the company currently has in stock.
- How do you interpret inventories?
- Increasing inventory levels may signal anticipated demand growth or supply chain buildup, whereas excessive levels relative to sales may indicate potential obsolescence or slow product uptake.
- How does inventories compare across companies?
- Inventory turnover varies significantly based on the complexity of the manufacturing process and the shelf life of the specific drug products.